ODN 21595
Modify Date: 2024-04-06 13:27:24
ODN 21595 structure
|
Common Name | ODN 21595 | ||
|---|---|---|---|---|
| CAS Number | 1964506-28-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ODN 21595ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE)[1]. |
| Name | ODN 21595 |
|---|
| Description | ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | ODN 21595 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs[1]. ODN 21595 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human PBMCs[1]. ODN 21595 (0.1, 1, 10 μM; 24 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human B-cells[1]. ODN 21595 (1, 10 μM; 48 h) displays a lower stimulatory activity and reduces significantly the CpG-ODN 2006 (100 nM) or imiquimod (5 μg/ml)-induced expression of CD86 or HLA-DR in CD20+ B-cells[1]. Cell Cytotoxicity Assay[1] Cell Line: human PBMCs Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 48 h Result: Showed no cytotoxic for human PBMCs. |
| References |
| No Any Chemical & Physical Properties |